Outpatient high‐dose melphalan in multiple myeloma patients
- 20 December 2006
- journal article
- Published by Wiley in Transfusion
- Vol. 47 (1) , 115-119
Abstract
BACKGROUND: The brief period of neutropenia and limited nonmarrow toxicity after high‐dose melphalan (HDM) provide a rationale for outpatient treatment.STUDY DESIGN AND METHODS: Our experience with HDM (140‐200 mg/m2) in 90 consecutive transplant episodes was retrospectively reviewed. Most patients were treated in an outpatient setting. Patients without a primary care provider (PCP) were electively admitted before the anticipated onset of neutropenia. Ceftriaxone was added to ciprofloxacin at the onset of neutropenia. All febrile patients were admitted.RESULTS: The median time from peripheral blood progenitor cell infusion to onset of neutropenia was 5 days (range, 4‐6 days), and the mean duration of neutropenia was 5 days (range, 4‐7 days). Thirty‐eight transplants (42%) were performed entirely in the outpatient setting. The mean duration of hospitalization was 2.2 days in patients not electively admitted. The use of ceftriaxone was associated with a decreased risk for fever (39% vs. 79%) and reduced duration of hospitalization (1.6 days vs. 4.5 days) for nonelectively admitted patients. There was no treatment‐related mortality.CONCLUSION: Ambulatory therapy with HDM is safe and can be achieved in a general outpatient setting. The predictable time to neutropenia allows even poor candidates for outpatient therapy to be admitted electively on Day +4. The apparent beneficial effect of ceftriaxone needs to be confirmed in randomized trials.Keywords
This publication has 11 references indexed in Scilit:
- Palifermin for Oral Mucositis after Intensive Therapy for Hematologic CancersNew England Journal of Medicine, 2004
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trialBlood, 2004
- Outpatient-based peripheral blood stem cell transplantation for patients with multiple myelomaThe Hematology Journal, 2004
- Single versus Double Autologous Stem-Cell Transplantation for Multiple MyelomaNew England Journal of Medicine, 2003
- A simplified approach to stem cell mobilization in multiple myeloma patients not previously treated with alkylating agentsBone Marrow Transplantation, 2003
- High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple MyelomaNew England Journal of Medicine, 2003
- Infections Caused by Viridans Streptococci in Patients with NeutropeniaClinical Infectious Diseases, 2002
- Comparison of 200 mg/m2 melphalan and 8 Gy total body irradiation plus 140 mg/m2 melphalan as conditioning regimens for peripheral blood stem cell transplantation in patients with newly diagnosed multiple myeloma: final analysis of the Intergroupe Francophone du Myelome 9502 randomized trialBlood, 2002
- Feasibility and cost-effectiveness of outpatient autotransplants in multiple myelomaBone Marrow Transplantation, 1997
- A Prospective, Randomized Trial of Autologous Bone Marrow Transplantation and Chemotherapy in Multiple MyelomaNew England Journal of Medicine, 1996